Finding ways to enhance the immune response against tumors by targeting specific proteins in T cells.
Identification of molecular glues targeting FoxP3 to modulate Treg suppressive function and enhance anti-tumor immunity
['FUNDING_FELLOWSHIP'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10993888
This study is looking at a way to make cancer treatments work better by targeting a protein that helps control certain immune cells, with the hope of boosting your body's ability to fight tumors during immunotherapy.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10993888 on ClinicalTrials.gov |
What this research studies
This research focuses on improving cancer treatment by targeting a specific protein called FoxP3, which plays a crucial role in regulating T regulatory cells (Tregs) that suppress the immune response. By chemically modifying the ubiquitin proteasome system, the researchers aim to reduce the suppressive function of Tregs, thereby enhancing the body's ability to fight tumors. The study seeks to develop new therapeutics that can more effectively modulate Treg activity, potentially leading to better outcomes for patients undergoing immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are currently treated with immunotherapy but have not responded effectively due to high levels of Tregs.
Not a fit: Patients who do not have cancer or those whose tumors are not influenced by Treg activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by improving the immune system's ability to attack tumors.
How similar studies have performed: Other research has shown promise in targeting Treg functions to enhance anti-tumor immunity, indicating that this approach could be viable.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TANG, AMY — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: TANG, AMY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.